Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: A longitudinal, randomized trial in young Ugandan children

Clinical Infectious Diseases

Volumn 49, Issue 11, 2009, Pages 1629-1637

  Arinaitwe, Emmanuel ^a   Sandison, Taylor G ^d   Wanzira, Humphrey ^a   Kakuru, Abel ^a   Homsy, Jaco ^b   Kalamya, Julius ^b   Kamya, Moses R ^c   Vora, Neil ^e   Greenhouse, Bryan ^e   Rosenthal, Philip J ^e   Tappero, Jordan ^b   Dorsey, Grant ^e  

^a MAKERERE UNIVERSITY   (Uganda)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUOCOTECXIN; HEMOGLOBIN; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; NONHUMAN; OUTCOMES RESEARCH; PARASITE; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RISK ASSESSMENT; TREATMENT OUTCOME; UGANDA; VOMITING;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; QUINOLINES; TREATMENT OUTCOME; UGANDA;

EID: 72849113797     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/647946     Document Type: Article

References (19)

1. World Health Organization. WHO guidelines for the treatment of malaria, 2006. Geneva, Switzerland: World Health Organization, 2006. Technical document WHO/HTM/MAL/2006.1108.
2. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360:2031-2038 (Pubitemid 36026582) (Pubitemid 36026582)
3. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210-2219
4. Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007; 2:e20. (Pubitemid 46860146) (Pubitemid 46860146)
5. Karema C, Fanello CI, Van Overmeir C, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006; 100:1105-1111 (Pubitemid 44464010) (Pubitemid 44464010)
6. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007; 101:858-866
7. Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE 2008; 3:e2390.
8. Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007; 45:1453-1461
9. Skinner-Adams TS, McCarthy JS, Gardiner DL, Andrews KT. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol 2008; 24:264-271
10. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006; 75:219-225 (Pubitemid 46941334)
11. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol 1993; 58:283-292 (Pubitemid 23076417)
12. Greenhouse B, Myrick A, Dokomajilar C, et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 2006; 75:836-842 (Pubitemid 351627527)
13. World Health Organization. Global AMDP database-AFRO. Available at: http://www.who.int/malaria/amdp/amdp-afro.htm. Accessed 7 December 2008.
14. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+ sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365:1474-1480 (Pubitemid 40591692) (Pubitemid 40591692)
15. Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; 365:1467-1473 (Pubitemid 40591691) (Pubitemid 40591691)
16. Bukirwa H, Yeka A, Kamya MR, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006; 1:e7.
17. Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin- piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008; 52:1052-1061 (Pubitemid 351358388) (Pubitemid 351358388)
18. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 2008; 7:9.
19. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008; 52:1589-1596 (Pubitemid 351614647) (Pubitemid 351614647)